Agriculture is the dominating land-use in the EU member states covering nearly half of the surface area. Using herbicides to reduce weed competition in agricultural areas can adversely affect Non-Target Terrestrial Plants (NTTP) growing in field margins. According to the EFSA Scientific Opinion on NTTPs an important protection goal is to maintain the biodiversity of plant species in agricultural areas. EFSA recommends to include also non-crop species mentioned in OECD guidelines (OECD 208 and 227) in the testing and to assess not only vegetative but also generative endpoints during the plant life-cycle such as flowering and seed production. The objectives of this study were to evaluate the feasibility of assessing generative endpoints of crop and non-crop species for NTTP regulatory testing under greenhouse conditions and to assess if generative endpoints are more sensitive than vegetative endpoints. The experimental design consisted of one control and four herbicide (Atlantis® WG) application rates, with 6 replicates each. The application rates of the test substance were the maximum field rate and 30%, 10% and 3% of the field rate. Biomass, plant height, flowering, seed production as well as seedling emergence of the F1 generation were assessed. The study shows a feasible approach to assess vegetative and generative endpoints of (non-) crops species under greenhouse conditions on the basis of the OECD guideline 227. The vegetative endpoints plant height and biomass were not more sensitive if assessed during the generative growth stage when compared to the vegetative growth stage of the plants. In contrast to that, the generative endpoint seed production was partly more sensitive in comparison to the vegetative endpoints biomass and plant height. For regulatory NTTP studies, 5 or more test substance rates at non-lethal levels should be tested so to allow the determination of ER10/50 values for vegetative and generative endpoints.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7064193 | PMC |
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0230155 | PLOS |
J Pathol Clin Res
January 2025
Department of Urology, University of Duisburg-Essen, Essen, Germany.
Distinct molecular subtypes of muscle-invasive bladder cancer (MIBC) may show different platinum sensitivities. Currently available data were mostly generated at transcriptome level and have limited comparability to each other. We aimed to determine the platinum sensitivity of molecular subtypes by using the protein expression-based Lund Taxonomy.
View Article and Find Full Text PDFBackground: Continuous anticoagulation based on the CHA2DS2-VASc score is recommended to prevent embolism caused by atrial fibrillation (AF), but it does not consider AF episodes. The Apple Watch's continuous heart rhythm monitoring and fast-acting direct oral anticoagulants (DOACs) could enable precise, episode-tailored anticoagulation, reducing bleeding risks while preventing stroke. This study evaluates Apple Watch-guided personalized anticoagulation therapy, adjusting DOAC usage based on real-time AF detection.
View Article and Find Full Text PDFJ Clin Endocrinol Metab
January 2025
Department of Neurology, Weill Cornell Medicine, New York NY, USA.
Accumulating evidence suggests that the effects of menopausal hormone therapy (MHT) on risk of Alzheimer's disease (AD) and all-cause dementia are influenced by timing of initiation relative to age and time-since-menopause and the type of formulation. Randomized clinical trials (RCTs) of MHT conducted in older postmenopausal women indicate an increased risk of dementia. While RCTs conducted in midlife are lacking, observational research has provided evidence for associations between midlife estrogen-only therapy (ET) use and a reduced risk of AD dementia, whereas estrogen-progestogen therapy (EPT) is associated with more variable outcomes.
View Article and Find Full Text PDFJpn J Clin Oncol
January 2025
Kindai University Hospital, 377-2 Onohigashi, Osakasayama, 589-8511, Osaka, Japan.
Background: The phase 3 open-label KEYNOTE-426 study demonstrated that first-line pembrolizumab plus axitinib improved overall survival (OS) and progression-free survival (PFS) versus sunitinib for metastatic renal cell carcinoma (mRCC) in a global population. This subgroup analysis investigated the efficacy and safety of pembrolizumab-axitinib versus sunitinib in patients enrolled in KEYNOTE-426 in East Asia (Japan, South Korea, and Taiwan).
Methods: Adults with clear cell mRCC were randomly assigned 1:1 to receive intravenous pembrolizumab 200 mg every 3 weeks with oral axitinib 5 mg twice daily or oral sunitinib 50 mg once daily (4 weeks on/2 weeks off).
Leukemia
January 2025
Department of Hematology, Mayo Clinic Rochester, Rochester, MN, USA.
In the MAIA study (median follow-up, 56.2 months), daratumumab plus lenalidomide and dexamethasone (D-Rd) significantly improved progression-free survival (PFS) and overall survival versus lenalidomide and dexamethasone (Rd) alone in transplant-ineligible newly diagnosed multiple myeloma (NDMM). In this post hoc analysis of clinically important subgroups in MAIA (median follow-up, 64.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!